PMA device
Helistat Absorbable Collagen Hemostatic Sponge/OraFOAM Absorbable Collagen Hemostatic Sponge
Integra LifeSciences Corporation · Agent, Absorbable Hemostatic, Collagen Based (LMF, Class III) · First FDA decision Sep 20, 2006, newest Mar 13, 2019Surgical bleeding and hemostasis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
1
Naming "Helistat"
MAUDE reports
15
Brand "Helistat", since 2015
PubMed studies
19
Mentioning "Helistat"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Helistat Absorbable Collagen Hemostatic Sponge/OraFOAM Absorbable Collagen Hemostatic Sponge
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Helistat Absorbable Collagen Hemostatic Sponge/OraFOAM Absorbable Collagen Hemostatic SpongePMA supplement
P850010-S082 · Decided Mar 13, 2019 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- HELISTAT ABSORBABLE COLLAGEN HEMOSTATIC AGENTSPMA supplement
P850010-S029 · Decided Mar 26, 2009 · 52 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- HELISTAT ABSORBABLE COLLAGEN HEMOSTATIC AGENTSPMA supplement
P850010-S019 · Decided Sep 20, 2006 · 355 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Helistat", any status and sponsor, newest update first.
- Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site AugmentationStatus unknown
Hailey BivensAcademic, hospital or other
NCT05961566 · 40 participants (planned) · Start Oct 1, 2023 · Primary completion Sep 30, 2024
Device: Use of collagen matrix after subepithelial connective tissue graft harvest · For: Recession, Gingival
Sites: Dallas, Texas
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Helistat", and for the whole product code for context.
This brand
15 reports: 0 malfunction, 15 injury, 0 death
Whole product code LMF
1,445 reports: 207 malfunction, 1,171 injury, 61 death
Newest reports for this brand
2648988-2019-00087 · Received Nov 6, 2019 · Event dated Mar 1, 2019
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cerebrospinal Fluid Leakage
2648988-2019-00090 · Received Nov 6, 2019 · Event dated Mar 1, 2019
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cerebrospinal Fluid Leakage
2648988-2019-00086 · Received Nov 6, 2019 · Event dated Mar 1, 2019
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cerebrospinal Fluid Leakage
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Integra LifeSciences Corporation
Z-1289-2013 · Started Mar 28, 2013 · Posted by FDA May 10, 2013
Reason given: Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products.
Cause as FDA categorized it: Process control · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Integra LifeSciences Corporation
Z-1290-2013 · Started Mar 28, 2013 · Posted by FDA May 10, 2013
Reason given: Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products.
Cause as FDA categorized it: Process control · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Integra LifeSciences Corporation
Z-1302-2013 · Started Mar 28, 2013 · Posted by FDA May 10, 2013
Reason given: Due to the process deviation, product lots in question may have been released with higher levels of pyrogens than permitted by the specifications for the products.
Cause as FDA categorized it: Process control · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Published research
The most relevant PubMed records for "Helistat"[tiab]. The summary above synthesizes these.
- Comparison of two topical collagen-based hemostatic sponges during cardiothoracic procedures.
Zwischenberger JB, Brunston RL, Swann JR, et al. · J Invest Surg · 1999Clinical Trial, Comparative Study
- Collagen-hydroxyapatite composite enhances regeneration of calvaria bone defects in young rats but postpones the regeneration of calvaria bone in aged rats.
Tcacencu I, Wendel M · J Mater Sci Mater Med · 2008Research Support, Non-U.S. Gov't
- Advances in the development and optimization strategies of the hemostatic biomaterials.
Guo Y, Cheng N, Sun H, et al. · Front Bioeng Biotechnol · 2022Review
- Comparative in vitro study of commercially available products for alveolar ridge preservation.
Jones K, Williams C, Yuan T, et al. · J Periodontol · 2022Comparative Study
- Comparative in vitro analysis of topical hemostatic agents.
Wagner WR, Pachence JM, Ristich J, et al. · J Surg Res · 1996Comparative Study, Research Support, Non-U.S. Gov't
- Sponge-like processed D-periodic self-assembled atelocollagen supports bone formation in vivo.
Borrego-González S, Rico-Llanos G, Becerra J, et al. · Mater Sci Eng C Mater Biol Appl · 2021
- Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model.
Fischgrund JS, James SB, Chabot MC, et al. · J Spinal Disord · 1997Research Support, Non-U.S. Gov't
- Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration.
Hollinger JO, Schmitt JM, Buck DC, et al. · J Biomed Mater Res · 1998Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application.
Lang A, Kirchner M, Stefanowski J, et al. · Acta Biomater · 2019Research Support, Non-U.S. Gov't
- In vitro resistance of artificial connective tissues to human bile and pancreatic juice.
Aprahamian M, Damgé C, Kerr-Conte J, et al. · Biomaterials · 1992Comparative Study, Research Support, Non-U.S. Gov't
- Histologic and immunohistochemical features in biopsy sites in which bovine collagen matrix was used for hemostasis.
Smith KJ, Skelton HG, Barrett TL, et al. · J Am Acad Dermatol · 1996Comparative Study
- Bone regeneration using rhBMP-2 induction in hemimandibulectomy type defects of elderly sub-human primates.
Boyne PJ, Salina S, Nakamura A, et al. · Cell Tissue Bank · 2006Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LMF.
- SURGIFOAM® Absorbable Gelatin SpongeFerrosan Meidcal Devices A/S · PMA 2026
- Floseal Hemostatic MatrixBaxter Healthcare Corp · PMA 2015
- Vitagel Surgical HemostatStryker Corp. · PMA 2013
- SURGIFLO Hemostatic Matrix Kit with ThrombinFerrosan Meidcal Devices A/S · PMA 2025
- Instat Collagen Absorbable HemostatETHICON, Inc. · PMA 2007
- Avitene Flowable Collagen HemostatDavol Inc., Sub. C. R. Bard, Inc. · PMA 2025
- Collastat Absorbable Collagen Hemostatic AgentsIntegra LifeSciences Corporation · PMA 2009
- Floseal (R) Matrix Hemostatic Sealant and Proceed (Tm) Hemostatic SealantBaxter Healthcare Corp · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.